MDT
Medtronic plc NYSE Listed May 2, 1973$79.34
+1.54%
vs $78.14
Mkt Cap $102.3B
52w Low $73.75
17.7% of range
52w High $105.35
50d MA $80.14
200d MA $91.91
P/E (TTM)
22.0x
EV/EBITDA
12.9x
P/B
2.1x
Debt/Equity
0.6x
ROE
9.2%
P/FCF
19.7x
RSI (14)
64.90
ATR (14)
$1.69
Beta
0.76
50d MA
$80.14
200d MA
$91.91
Avg Volume
11.6M
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Building Two, Parkmore Business Park West · Galway 2 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | AMC | 1.54 | 1.55 | +0.6% | 77.95 | +2.6% | +5.1% | -0.3% | -1.2% | +1.6% | -2.1% | — |
| Feb 17, 2026 | AMC | 1.34 | 1.36 | +1.5% | 96.41 | -0.4% | +2.2% | -0.9% | -0.7% | +1.8% | -1.9% | — |
| Nov 18, 2025 | AMC | 1.31 | 1.36 | +3.8% | 100.80 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% | — |
| Aug 19, 2025 | AMC | 1.23 | 1.26 | +2.4% | 89.90 | +0.5% | +3.7% | -2.3% | +1.8% | -0.7% | +0.2% | — |
| May 21, 2025 | AMC | 1.58 | 1.62 | +2.5% | 84.41 | -1.3% | -4.1% | -0.3% | +0.6% | +0.1% | +1.4% | — |
| Feb 18, 2025 | AMC | 1.36 | 1.39 | +2.2% | 86.07 | -0.1% | +1.1% | +1.1% | +2.3% | +0.3% | +0.3% | — |
| Nov 19, 2024 | AMC | 1.25 | 1.26 | +0.8% | 85.00 | -0.3% | -1.0% | +0.7% | +1.7% | -0.5% | -0.1% | — |
| Aug 20, 2024 | AMC | 1.20 | 1.23 | +2.5% | 85.38 | +0.6% | +2.5% | +0.3% | +0.6% | +1.1% | -0.6% | — |
| May 23, 2024 | AMC | 1.45 | 1.46 | +0.7% | 81.38 | -0.5% | +1.1% | -0.4% | -0.6% | -1.1% | +1.0% | — |
| Feb 20, 2024 | AMC | 1.26 | 1.30 | +3.2% | 85.85 | +0.8% | +0.1% | -1.0% | +0.7% | -2.3% | +0.2% | — |
| Nov 21, 2023 | AMC | 1.18 | 1.25 | +5.9% | 78.62 | +0.4% | -0.3% | +0.8% | +0.0% | -0.5% | +0.3% | — |
| Aug 22, 2023 | AMC | 1.11 | 1.20 | +8.1% | 83.72 | +1.1% | -0.0% | -3.1% | +1.4% | -1.0% | +0.8% | — |
| May 25, 2023 | AMC | 1.56 | 1.57 | +0.6% | 83.54 | -0.9% | -2.5% | +1.3% | +0.3% | -0.0% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4 | BTIG Research | Upgrade | Neutral → Buy | $90 | $77.95 | $80.00 | +2.6% | +5.1% | -0.3% | -1.2% | +1.6% | -2.1% |
| May 21 | Goldman | Reiterates | Neutral | $84 | $78.15 | $77.49 | -0.8% | +0.0% | +0.6% | -1.3% | -2.1% | -0.5% |
| Apr 22 | UBS | Maintains | Neutral → Neutral | — | $82.00 | $82.90 | +1.1% | +1.5% | +0.7% | -0.6% | -0.5% | -1.2% |
| Apr 15 | Truist | Maintains | Hold → Hold | — | $88.12 | $87.86 | -0.3% | -1.2% | -1.7% | +0.6% | -1.4% | -3.5% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $87.21 | $87.00 | -0.2% | +0.9% | +0.1% | -1.2% | -1.7% | +0.6% |
| Apr 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $88.65 | $87.91 | -0.8% | -0.8% | -0.8% | +0.9% | +0.1% | -1.2% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $86.28 | $85.99 | -0.3% | +0.2% | +2.6% | -0.8% | -0.8% | +0.9% |
| Apr 6 | Argus | Maintains | Buy → Buy | — | $86.63 | $86.43 | -0.2% | -0.4% | +0.2% | +2.6% | -0.8% | -0.8% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $86.63 | $86.43 | -0.2% | -0.4% | +0.2% | +2.6% | -0.8% | -0.8% |
| Apr 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $86.65 | $86.58 | -0.1% | -0.7% | +0.7% | -0.4% | +0.2% | +2.6% |
| Apr 1 | Barclays | Maintains | Overweight → Overweight | — | $86.65 | $86.58 | -0.1% | -0.7% | +0.7% | -0.4% | +0.2% | +2.6% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $87.89 | $87.30 | -0.7% | -0.3% | -0.6% | -1.6% | +1.1% | -0.7% |
| Mar 10 | Needham | Maintains | Buy → Buy | — | $91.34 | $91.21 | -0.1% | -1.6% | -1.0% | -1.8% | -0.3% | +1.3% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $96.41 | $96.00 | -0.4% | +2.2% | -0.9% | -0.7% | +1.8% | -1.9% |
| Feb 18 | JP Morgan | Maintains | Neutral → Neutral | — | $96.41 | $96.00 | -0.4% | +2.2% | -0.9% | -0.7% | +1.8% | -1.9% |
| Feb 18 | Baird | Maintains | Neutral → Neutral | — | $96.41 | $96.00 | -0.4% | +2.2% | -0.9% | -0.7% | +1.8% | -1.9% |
| Feb 17 | Needham | Maintains | Buy → Buy | — | $99.49 | $95.88 | -3.6% | -3.1% | +2.2% | -0.9% | -0.7% | +1.8% |
| Feb 9 | Needham | Upgrade | Hold → Buy | — | $102.90 | $103.59 | +0.7% | -1.2% | -0.2% | -0.3% | -0.2% | -1.4% |
| Feb 4 | UBS | Maintains | Neutral → Neutral | — | $103.18 | $103.32 | +0.1% | -1.3% | +1.1% | -0.0% | -1.2% | -0.2% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $98.69 | $98.95 | +0.3% | -1.2% | -0.6% | -0.5% | +2.4% | +0.3% |
| Jan 8 | Barclays | Maintains | Overweight → Overweight | — | $99.77 | $99.62 | -0.2% | -1.1% | -1.2% | -0.6% | -0.5% | +2.4% |
| Jan 6 | William Blair | Upgrade | Market Perform → Outperform | — | $97.36 | $98.06 | +0.7% | +3.0% | -0.5% | -1.1% | -1.2% | -0.6% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $98.30 | $98.69 | +0.4% | +0.2% | +0.2% | -0.9% | -0.2% | -0.2% |
| Nov 20 | Truist | Maintains | Hold → Hold | — | $100.34 | $100.37 | +0.0% | -1.0% | +1.9% | +2.0% | +2.1% | -0.3% |
| Nov 20 | Barclays | Maintains | Overweight → Overweight | — | $100.34 | $100.37 | +0.0% | -1.0% | +1.9% | +2.0% | +2.1% | -0.3% |
| Nov 19 | UBS | Maintains | Neutral → Neutral | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% |
| Nov 19 | RBC Capital | Maintains | Outperform → Outperform | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% |
| Nov 19 | Wells Fargo | Maintains | Overweight → Overweight | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% |
| Nov 19 | Goldman Sachs | Upgrade | Sell → Neutral | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% |
| Nov 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% |
| Nov 19 | Baird | Maintains | Neutral → Neutral | — | $100.80 | $100.99 | +0.2% | -0.5% | -1.0% | +1.9% | +2.0% | +2.1% |
| Nov 13 | JP Morgan | Maintains | Neutral → Neutral | — | $95.81 | $95.00 | -0.8% | +0.3% | -0.3% | +0.4% | +4.7% | -0.5% |
| Oct 15 | Truist | Maintains | Hold → Hold | — | $96.54 | $96.07 | -0.5% | -1.2% | -0.3% | +0.8% | +0.1% | -0.1% |
| Oct 9 | Stifel | Maintains | Hold → Hold | — | $97.87 | $98.19 | +0.3% | -1.4% | -1.1% | +0.1% | +1.0% | -1.2% |
| Oct 7 | Citigroup | Maintains | Buy → Buy | — | $98.43 | $98.33 | -0.1% | -0.1% | -0.5% | -1.4% | -1.1% | +0.1% |
| Aug 26 | Argus | Maintains | Buy → Buy | — | $92.04 | $92.43 | +0.4% | +0.2% | -0.1% | -0.1% | +0.9% | +0.6% |
| Aug 21 | Citigroup | Maintains | Buy → Buy | — | $93.22 | $93.32 | +0.1% | -2.3% | +1.8% | -0.7% | +0.2% | -0.1% |
| Aug 21 | Truist | Maintains | Hold → Hold | — | $93.22 | $93.32 | +0.1% | -2.3% | +1.8% | -0.7% | +0.2% | -0.1% |
| Aug 20 | Bernstein | Maintains | Outperform → Outperform | — | $89.90 | $90.36 | +0.5% | +3.7% | -2.3% | +1.8% | -0.7% | +0.2% |
| Aug 20 | UBS | Maintains | Neutral → Neutral | — | $89.90 | $90.36 | +0.5% | +3.7% | -2.3% | +1.8% | -0.7% | +0.2% |
| Aug 20 | Baird | Maintains | Neutral → Neutral | — | $89.90 | $90.36 | +0.5% | +3.7% | -2.3% | +1.8% | -0.7% | +0.2% |
| Aug 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $89.90 | $90.36 | +0.5% | +3.7% | -2.3% | +1.8% | -0.7% | +0.2% |
| Aug 14 | Needham | Maintains | Hold → Hold | — | $92.91 | $92.85 | -0.1% | -1.0% | +1.1% | -0.2% | -3.1% | +3.7% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $89.22 | $89.59 | +0.4% | +0.6% | -0.3% | +0.1% | +0.1% | +2.2% |
| Jul 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $89.73 | $89.70 | -0.0% | -0.6% | +0.6% | -0.3% | +0.1% | +0.1% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $88.58 | $88.83 | +0.3% | +0.5% | +0.4% | +0.6% | -0.2% | -0.6% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $87.67 | $87.56 | -0.1% | +1.0% | +0.5% | +0.4% | +0.6% | -0.2% |
| Jun 30 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $86.02 | $86.65 | +0.7% | +1.3% | +1.8% | -0.5% | +0.1% | -0.8% |
| Jun 6 | Needham | Maintains | Hold → Hold | — | $87.00 | $87.29 | +0.3% | +0.5% | +0.0% | +0.6% | +0.1% | +0.5% |
| May 22 | RBC Capital | Maintains | Outperform → Outperform | — | $84.41 | $83.28 | -1.3% | -4.1% | -0.3% | +0.6% | +0.1% | +1.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | KIIL HARRY SKIPOff | EVP & President Cardiovascular | Sell | 228 | $80.45 | $18K | 37,227 | -2.11% | +1.17% |
| Jun 8, 2026 | KIIL HARRY SKIPOff | EVP & President Cardiovascular | Sell | 3,961 | $80.44 | $319K | 37,455 | -2.11% | +1.17% |
8-K
Medtronic plc -- 8-K Filing
Jun 3
8-K
MiniMed Group, Inc. -- 8-K Filing
Medtronic appointed a seasoned executive from Danaher with extensive regulatory and quality expertise to lead its Engineering and Innovation Center, strengthening the company's product development capabilities.
May 18
8-K · 5.02
!!! Very High
Medtronic plc -- 8-K 5.02: Executive Change
Medtronic promotes Kweli Thompson to lead its Neuroscience Portfolio as Executive Vice President starting June 2026, signaling strategic focus on this high-growth business segment.
May 18
8-K · 7.01
! Medium
Medtronic plc -- 8-K 7.01: Regulation FD Disclosure
Medtronic experienced a cybersecurity breach but reports no impact to products, operations, or patient safety, mitigating near-term investor concerns about operational disruption.
Apr 27
8-K · 7.01
! Medium
MiniMed Group, Inc. -- 8-K 7.01: Regulation FD Disclosure
Medtronic disclosed an unauthorized third-party breach of its IT systems; the company activated incident response protocols and engaged external cybersecurity experts to investigate and remediate the security breach.
Apr 27
8-K · 5.02
!!! Very High
SkinHealth Systems Inc. -- 8-K 5.02: Executive Change
SkinHealth Systems appointed Kenneth Tripp as director and Dr. Sachin Shridharani as Senior Vice President, signaling management strengthening under new leadership.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Vafa Jamali's appointment as director signals potential strategic shifts in governance and decision-making, warranting investor attention to board composition changes affecting corporate direction and oversight quality.
Apr 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I cannot provide a meaningful analysis of this filing because the summary provided is incomplete and contains only procedural language referencing exhibits rather than details about the actual executive change, compensation, or departure rationale.
Mar 27
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Medtronic will face $0.04 per-share dilution in Q4 FY2026 from its MiniMed IPO, creating near-term EPS headwinds that investors should factor into earnings estimates.
Mar 24
8-K · 5.02
!!! Very High
MiniMed Group, Inc. -- 8-K 5.02: Executive Change
Brian Sandstrom's resignation as director of MiniMed Group signals potential leadership transitions that investors should monitor for impact on board oversight and strategic direction.
Mar 9
8-K · 5.02
!!! Very High
Shoulder Innovations, Inc. -- 8-K 5.02: Executive Change
Shoulder Innovations replaced director Pardo with Andrew Hykes as Class I director, signaling potential strategic shifts in board composition and governance oversight.
Mar 2
8-K
Medtronic plc -- 8-K Filing
Medtronic exceeded Q3 guidance with $9.0 billion in revenue (8.7% reported growth) and $1.36 non-GAAP EPS, while maintaining full-year FY26 guidance and achieving strong 80% growth in Cardiac Ablation Solutions.
Feb 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 83,333,833 | $7.2B | New | Mar 2026 |
| 2 | Jpmorgan Chase & Co | 50,973,541 | $4.4B | Reduced | Mar 2026 |
| 3 | Morgan Stanley | 40,445,150 | $3.9B | — | Dec 2025 |
| 4 | Capital Research Global Investors | 41,926,590 | $3.6B | Added | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 33,450,558 | $2.9B | New | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 26,015,003 | $2.3B | Added | Mar 2026 |
| 7 | First Eagle Investment Management, Llc | 20,089,390 | $1.7B | Added | Mar 2026 |
| 8 | Invesco Ltd. | 16,786,998 | $1.5B | Added | Mar 2026 |
| 9 | Capital World Investors | 16,507,316 | $1.4B | Added | Mar 2026 |
| 10 | Bank Of New York Mellon Corp | 15,501,869 | $1.3B | Reduced | Mar 2026 |
| 11 | Royal Bank Of Canada | 14,179,817 | $1.2B | Added | Mar 2026 |
| 12 | Franklin Resources Inc | 14,175,679 | $1.2B | Added | Mar 2026 |
| 13 | Northern Trust Corp | 12,036,821 | $1.0B | Added | Mar 2026 |
| 14 | Schroder Investment Management Group | 8,606,604 | $746M | Added | Mar 2026 |
| 15 | Dodge & Cox | 7,694,608 | $667M | Reduced | Mar 2026 |
| 16 | Aristotle Capital Management, Llc | 6,929,619 | $666M | Reduced | Dec 2025 |
| 17 | Wells Fargo & Company/mn | 7,514,778 | $651M | New | Mar 2026 |
| 18 | Raymond James Financial Inc | 7,382,158 | $638M | Reduced | Mar 2026 |
| 19 | Ubs Group Ag | 6,412,252 | $556M | Added | Mar 2026 |
| 20 | Amundi | 6,070,236 | $526M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$102.34B
Enterprise Value
$118.97B
P/E (TTM)
21.98x
Forward P/E
13.06x
PEG Ratio
0.75x
P/B
2.11x
P/S
3.05x
P/FCF
19.74x
EV/EBITDA
12.91x
Shares Out
1.29B
Financials (TTM)
Revenue
$33.54B
Net Income
$4.66B
EBITDA
$9.22B
Free Cash Flow
$5.18B
Op Cash Flow
$7.04B
EPS Basic
$3.63
EPS Diluted
$3.61
EPS Forward
$6.07
Gross Margin
65.3%
Op Margin
17.8%
Net Margin
13.9%
Balance Sheet
Total Assets
$91.68B
Total Liab.
$43.42B
Total Equity
$48.26B
Cash
$8.96B
LT Debt
$25.59B
Book Value/Sh
$37.54
Debt/Equity
0.59x
Current Ratio
1.85
Quick Ratio
1.42
Returns & Growth
ROE
9.2%
ROA
4.9%
ROIC
6.1%
Rev Growth YoY
+3.6%
EPS Growth YoY
+31.1%
Price Returns
2W
-4.1%
1M
-8.8%
3M
-24.4%
6M
-29.9%
12M
-11.1%
Technicals
52W High
$105.35
52W Low
$73.75
50d MA
$80.14
200d MA
$91.91
RSI (14)
64.90
ATR (14)
$1.69
Beta
0.76
Avg Volume
11.6M
Dividends
Div Rate
$2.79
Div Yield
3.5%
Frequency
4
Ex-Div Date
Mar 27, 2026
Analyst Price Targets
Consensus
$109.50
High
$120.00
Low
$95.00
Median
$111.50
Data updated apr 26, 2026 11:43am
· Source: financialmodelingprep.com